SARS-CoV-2 Neutralizing Antibody Research and Development
White Paper Jan 26, 2021
In response to the COVID-19 pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), researchers across the globe have united in efforts to develop effective therapeutic and preventive strategies against the virus.
Neutralizing antibodies are currently being investigated as one such strategy against SARS-CoV-2, as they have the potential to block the virus from infecting host cells.
Download this whitepaper to learn more about:
- The antiviral mechanism of SARS-CoV-2 neutralizing antibodies
- Global efforts to develop neutralizing antibody products against SARS-CoV-2
- Mutated SARS-CoV-2 and it’s impact on the protective ability of neutralizing antibodies
Related White Papers
One of the common molecular analyses is the determination of a lead molecule’s binding kinetics and affinity to the target. This warrants the need for analytical instruments capable of characterizing such molecules. Download this whitepaper to discover an approach that accurately measures multiple high-affinity interactions over long run times.READ MORE
Preventive measures, accurate disease diagnostics and effective contact tracing are still considered fundamental in efforts to combat the SARS-CoV-2 pandemic. Download this whitepaper to discover serological testing methods, antigen testing methods and the impact of COVID-19 variants and antibody cross reactivity.READ MORE
Data accessibility has been a challenge because the lab operator’s relationship to data is usually prescribed by preset LIMS features. Using data science algorithms, it is now possible to process and integrate all LIMS and enterprise data to provide valuable insights and timely, meaningful recommendations. Access this whitepaper to discover a technology that provides a holistic view of your data, delivers statistical and business analysis and increases productivity.